HOME >> MEDICINE >> NEWS
Ovarian carcinoma, ethnicity, and survival

African-American women with ovarian carcinoma have a 30% greater risk of death from any cause and are more likely to die earlier when compared to Caucasian women with ovarian cancer. Findings in a recent study published in the March 15, 2002, issue of CANCER* indicate that ethnicity itself is a risk factor in ovarian cancer survival even after adjustment for prognostic factors that showed ethnic differences. Differences in prognostic factors were observed in age at diagnosis, marital status, stage of tumor, and site-specific surgical treatment.

Ovarian cancer causes more deaths per year than all other female reproductive cancers. Ethnicity, parity, oral contraception use, and breast feeding are all predictive factors for development of ovarian cancer. Factors that predict poor prognosis include higher disease stage and older age. Other studies have also shown that African-Americans with ovarian cancer have higher mortality rates than Caucasians with ovarian cancer. While ethnicity is a risk factor, little is known about the differences in prognostic factors between Caucasians and African-Americans with ovarian cancer that could effect survival. In a retrospective study of over 13,000 women with ovarian cancer, Barnholtz-Sloan et al analyzed data for differences in prognostic factors between Caucasians and African-Americans and the effect of these differences on ovarian cancer survival.

Data from 12,285 Caucasian women and 798 African-American women diagnosed with primary, malignant ovarian carcinoma was analyzed from the Surveillance, Epidemiology, and End Results (SEER) Program. SEER is a population-based national cancer surveillance database with demographic, clinical, treatment and survival information on men and women diagnosed with cancer. Factors included the database and analyzed in this study include marital status, age at diagnosis, tumor stage, tumor histology and grade, lymph node involvement, site-specific surgical treatment, and
'"/>

Contact: David Greenberg
dgreenbe@wiley.com
212-850-6484
John Wiley & Sons, Inc.
14-Mar-2002


Page: 1 2

Related medicine news :

1. Ovarian cancer does have early warning signs, Mayo Clinic and Olmsted Medical Center find
2. Ovarian cancer rates across Europe
3. Ovarian tissue storage and later transplant shows promise for women infertile from cancer therapy
4. Ovarian Hormone Could Play Key Role In Easier, Safer Childbirth
5. Age, ethnicity, income impact exercise habits of elderly
6. Hormonal treatment improves survival in high-risk prostate cancer patients
7. Lack of clinical trial participation may contribute to lower survival rates
8. Alcohol relapse adversely affects 10-year liver transplant survival
9. Donor age has no affect on long-term liver transplant survival
10. Specialist care gives better rate of survival
11. Bevacizumab combined with chemotherapy prolongs survival for some patients with advanced lung cancer

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/21/2017)... ... ... Salveo for life, a company that distributes an effervescent lime-flavored drink called ... part of its presence to expand its market reach. , Using a formula developed ... nasty toxins as a result of drinking alcohol, eliminating those toxins quickly, whilst supporting ...
(Date:1/21/2017)... ... January 21, 2017 , ... Seamild, the largest manufacturer of oats ... of its owner and founder. As Oat is recognized globally as one of the ... personally as he believes it is a move to sow the seed of good ...
(Date:1/21/2017)... , ... January 21, 2017 , ... ... Alumni Relations, Dianne Travis-Teague, the electrifying line-up of events for its annual meeting ... family, friends, and community. “Coming Home 2017” will be held on Friday ...
(Date:1/21/2017)... Rosa, CA (PRWEB) , ... January 21, 2017 ... ... the opening of its new medical office in Petaluma, located at 167 Lynch ... casting room, access to SRO sports medicine and rehabilitation services and ...
(Date:1/21/2017)... ... January 21, 2017 , ... The ... Dr. Dan Holtzclaw in media for its creos™ line of bone regenerative products. ... Dr. Holtzclaw in which he utilizes creos™ allo.gain™ bone graft for a variety ...
Breaking Medicine News(10 mins):
(Date:1/21/2017)... 2017 ARMO BioSciences, Inc., a late-stage immuno-oncology ... Company,s lead investigational immuno-oncology drug AM0010 (PEGylated Interleukin-10) at ... Society of Clinical Oncology (ASCO), taking place January 19-21, ... "AM0010 induces the expansion of novel ... cells in the blood and tumors of our patients," ...
(Date:1/21/2017)... Research and Markets has announced the addition of the "Advanced ... End User - Forecast to 2025" report to their offering. ... The Global Advanced ... around 7.8% over the next decade to reach approximately $330.70 billion ... markets for Advanced Drug Delivery across all the given segments on ...
(Date:1/20/2017)... DUBLIN , Jan 20, 2017 ... Laboratory Testing Market By Type ([CBC, HGB/HCT, BMP, BUN Creatinine, Electrolyte ... Panel), By End-use, And Segment Forecasts, 2013 - 2024" report ... ... USD 198.5 billion by 2024 Introduction of innovative solutions ...
Breaking Medicine Technology:
Cached News: